Covid-19 roundup: Temasek leads a $250M raise for BioNTech as first Covid-19 mRNA vaccine data looms; China's military OKs first use of coronavirus vaccine
Singapore’s giant fund run by Temasek is putting some financial muscle behind BioNTech $BNTX as the Pfizer partner prepares to post the first cut of its data on their mRNA vaccine to combat Covid-19.
Temasek is leading a $250 million injection into the German biotech, one of a small pack of mRNA players attempting to field a vaccine to fight the global pandemic that’s been rattling the world. Moderna is in front of the mRNA pack with Phase III plans.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.